Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada
2007

Cancer Therapy Disparity in Canada

Sample size: 454 publication Evidence: moderate

Author Information

Author(s): Sunil Verma, Sehdev S., Joy A.A.

Primary Institution: Toronto–Sunnybrook Regional Cancer Centre

Hypothesis

The study investigates the disparity in access to aromatase inhibitor therapy for postmenopausal women with early-stage hormone-sensitive breast cancer across Canada.

Conclusion

There is significant disparity in access to aromatase inhibitors for breast cancer treatment across different provinces in Canada.

Supporting Evidence

  • One in nine Canadian women is expected to develop breast cancer in her lifetime.
  • Adjuvant therapy has significantly reduced breast cancer-specific mortality.
  • Access to aromatase inhibitors varies widely by province.

Takeaway

Some women in Canada can't get the same cancer medicine as others, which isn't fair. This study shows how different provinces handle this problem.

Methodology

The study involved an online survey of Canadian oncologists to assess treatment preferences and access to aromatase inhibitors.

Potential Biases

Potential bias in responses from oncologists based on their personal experiences and provincial guidelines.

Limitations

The study may not capture all factors influencing access to treatment across provinces.

Participant Demographics

Oncologists from 10 provinces in Canada participated in the survey.

Statistical Information

P-Value

0.007

Confidence Interval

95% CI: 0.71 to 0.95

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication